department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

KalVista Pharmaceuticals, Inc. ($KALV) · pharmadog

PUBLIC COMPANY

$KALVKalVista Pharmaceuticals, Inc.

Framingham, MA, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

1

marketed

1

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Marketed

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-IN…

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view KalVista Pharmaceuticals, Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$KALV

SEC CIK

0001348911

country

US

source

sec_tickers

top tags

mentioned in

0news items

entity-linker matched

$KALV

Insider activity

source: SEC Form 4

90d open-market buys

$0

0 transactions

90d open-market sells

$323K

4 transactions

net (buys − sells)

−$323K

non-derivative only

open-market buys + sells

Apr 17, 26SELLPalleiko Benjamin L· CHIEF EXECUTIVE OFFICER9,550 sh @ $20.22−$193K↗
Apr 17, 26SELLAudhya Paul K.· CHIEF MEDICAL OFFICER2,686 sh @ $20.22−$54K↗
Apr 17, 26SELLSweeny Nicole· Chief Commercial Officer1,862 sh @ $20.22−$38K↗
Apr 17, 26SELLPiekos Brian· Chief Financial Officer1,862 sh @ $20.22−$38K↗
Mar 26, 26SELLVenrock Healthcare Capital Partners III, L.P.· 21,386 sh @ $17.76−$380K↗
Mar 26, 26SELLVenrock Healthcare Capital Partners III, L.P.· 15,417 sh @ $18.82−$290K↗
Mar 26, 26SELLVenrock Healthcare Capital Partners III, L.P.· 3,183 sh @ $19.12−$61K↗
Mar 25, 26SELLVenrock Healthcare Capital Partners III, L.P.· 174,485 sh @ $16.95−$2.96M↗
Mar 25, 26SELLVenrock Healthcare Capital Partners III, L.P.· 160 sh @ $17.53−$3K↗
Mar 9, 26SELLPalleiko Benjamin L· CHIEF EXECUTIVE OFFICER6,693 sh @ $16.08−$108K↗
Feb 23, 26SELLPalleiko Benjamin L· CHIEF EXECUTIVE OFFICER10,034 sh @ $15.57−$156K↗
Feb 23, 26SELLAudhya Paul K.· CHIEF MEDICAL OFFICER5,354 sh @ $15.57−$83K↗
Feb 23, 26SELLYea Christopher· CHIEF DEVELOPMENT OFFICER4,347 sh @ $15.57−$68K↗
Feb 23, 26SELLSweeny Nicole· Chief Commercial Officer3,975 sh @ $15.57−$62K↗
Feb 23, 26SELLPiekos Brian· Chief Financial Officer1,767 sh @ $15.57−$28K↗
Feb 18, 26SELLAudhya Paul K.· CHIEF MEDICAL OFFICER1,163 sh @ $15.00−$17K↗
Feb 18, 26SELLYea Christopher· CHIEF DEVELOPMENT OFFICER1,109 sh @ $15.00−$17K↗
Feb 18, 26SELLPalleiko Benjamin L· CHIEF EXECUTIVE OFFICER1,038 sh @ $15.00−$16K↗
Feb 12, 26SELLPalleiko Benjamin L· CHIEF EXECUTIVE OFFICER3,354 sh @ $15.70−$53K↗

routine RSU / option mechanics (1)

Apr 16, 26option exerciseSweeny Nicole · Chief Commercial Officer6,250 sh

Data sources

last refreshed 28m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Active trials

phase4Safety and Effectiveness of Sebetralstat for Short-Term Prevention Before Procedures in People With Hereditary Angioedemanot yet recruitingn=100
phase3An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)active not recruitingn=145
—Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstatavailable
phase3Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or IIcompletedn=36
—

A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks

completed

n=88

—Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstatapproved for marketing

phase3PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trialactive not recruitingn=11

phase3A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)completedn=136

more trials →

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?